Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

Q: What type of study is this?

This is a Systematic Review study (also classified as: Meta-Analysis).

Hayley Vandenboom; Othman Salim Akhtar; Aniko Szabo; Ravi Narra; Meera Mohan; Anita D’Souza; Marcelo C. Pasquini; Binod Dhakal

doi:10.3324/haematol.2025.288174

August 13, 2025HaematologicaOpen Access

Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Share

Key Points

BCMA CAR-T therapy demonstrates a significant improvement in patient outcomes compared to bispecific antibodies.
The meta-analysis reveals a notable efficacy difference, particularly in relapse rates for patients with advanced disease.
Systematic review comparing clinical outcomes from several studies highlights the benefits of CAR-T cells in modifying the immune response.
Findings suggest both therapies are viable, but CAR-T may provide added survival advantages; further validation is needed.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Systematic review and meta-analysis show BCMA CAR-T and bispecific antibodies improve outcomes in relapsed multiple myeloma, suggesting effective treatment options.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vandenboom et al. (2025) studied this question.

synapsesocial.com/papers/68a368920a429f797332e0e4 https://doi.org/10.3324/haematol.2025.288174

View Full Paper

Ask AI

Bookmark

Share

Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading